Trial Profile
A Randomized Phase II Study of VEGF-Antisense Oligonucleotide (VEGF-AS) in Advanced Renal Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2008
Price :
$35
*
At a glance
- Drugs Veglin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 10 Mar 2008 New trial record.